Ticagrelor Monotherapy After Coronary Stenting: Like a Twilight Through the Looking Glass
- PMID: 33602442
- DOI: 10.1016/j.jcin.2020.12.039
Ticagrelor Monotherapy After Coronary Stenting: Like a Twilight Through the Looking Glass
Keywords: antiplatelet; percutaneous coronary intervention; stent; ticagrelor.
Conflict of interest statement
Funding Support and Author Disclosures Dr. Sibbing has received lecture fees from Bayer, Sanofi, AstraZeneca, Daiichi-Sankyo, Pfizer, and Roche Diagnostics; has received advisory board fees from Bayer, Sanofi, AstraZeneca, Daiichi-Sankyo, and Ferrer; and has received grant support from Roche Diagnostics. Dr. Cassese has received lecture fees from AstraZeneca.
Comment on
-
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis.JACC Cardiovasc Interv. 2021 Feb 22;14(4):444-456. doi: 10.1016/j.jcin.2020.11.046. JACC Cardiovasc Interv. 2021. PMID: 33602441
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical